What changes in your body?
GLP-1 is a natural hormone involved in appetite and blood sugar. Semaglutide acts like this hormone. Tirzepatide acts on both GLP-1 and another hormone called GIP.
These medicines help you feel full and may reduce hunger. They also help your body release insulin when blood sugar is high and reduce signals that tell the liver to release sugar.
They can slow how quickly food leaves your stomach. This is called delayed stomach emptying, not a complete stop in digestion. Food may sit in your stomach longer, especially early in treatment, so an old portion size can suddenly feel too large. This effect can lessen over time.
Tell your surgical or anesthesia team that you take this medicine before any procedure. They will give you specific instructions.
Common side effects, and what may help
Nausea, diarrhea, vomiting, constipation and stomach discomfort are common. Some people also notice reflux, burping, bloating, headache or fatigue. Symptoms often occur when starting or increasing a dose and may ease with time. Not everyone has them, and they cannot always be prevented.
Do not push through severe symptoms or increase your dose while struggling to eat or drink. Contact your prescriber before your next planned dose change.
Less appetite should not mean too little nourishment.

Eating too little: Skipping meals can leave you short on protein, vitamins and other nutrients. It can contribute to weakness, fatigue and loss of muscle tissue. It is not a shortcut to healthier progress.
Eating past fullness: Larger meals can worsen nausea, reflux and discomfort. Eat slowly, pause and stop when comfortably full. If you are hungry again later, a smaller meal or snack may be easier.
- Include protein regularly, alongside vegetables, fruit, carbohydrates and unsaturated fats.
- Add fiber slowly and pair it with adequate fluids. More fiber all at once is not always better.
- Sip water through the day. Follow your personal fluid limits if your clinician has given you any.
- Ask about resistance exercise and a registered dietitian, especially if it is hard to eat enough.
Dose changes and early progress
A check-in, not an automatic increase
Approved adult weight-management schedules for weekly Wegovy injections and Zepbound use gradual increases. Wegovy’s schedule typically steps up every four weeks, with a delay if a dose is not tolerated. Zepbound increases are spaced at least four weeks apart. Other products, formulations and indications have different instructions.
Your clinician decides whether to increase, wait or stay at an appropriate maintenance dose based on your response, side effects and treatment goals. Not everyone needs the highest dose. Starting doses help your body adjust and are not necessarily maintenance doses.
Compounded products are not FDA-approved, and microdosing is not an FDA-approved schedule. Follow your own written instructions. For a vial, confirm the dose in milligrams, concentration, injection volume and correct syringe with your care team. Never increase your dose, take it early or change syringe units on your own.
Your timeline may be different
Some people notice appetite changes early. For others, changes are gradual as treatment is adjusted. The first few weeks are not a pass-or-fail test.
The third and fourth months can still be part of gradual dose adjustment, depending on the medicine and your plan. They are not a guaranteed turning point. There is no promised month when noticeable progress will happen, and a lack of early change does not automatically mean you need a higher dose.
Response depends on several factors, including the medicine, dose, health history and eating and activity patterns. It cannot be explained simply as “your receptors need more.” If progress is limited, your clinician should review the whole plan.
Look at trends over time, not one weigh-in. Blood sugar, nutrition, daily function and how you feel may also matter to your care plan.
When the scale slows or stops
Weight change is not a straight line. Water retention, salt intake, menstrual changes and constipation can temporarily hide changes on the scale. A few flat days or an up-and-down week do not tell the whole story.
After weight decreases, a smaller body usually needs fewer calories. Your body may also adapt by using less energy than expected, while hunger signals can change. The habits that previously led to weight reduction may now maintain your new weight. That can be part of a real plateau, not a “fake stall” or a personal failure.
There is no universal six-week definition of a plateau. Studies and clinicians use different definitions. Six weeks without a downward trend can be a useful reason to check in, but it is not a diagnostic cutoff or proof that treatment has stopped working.
For example, one analysis of tirzepatide trials defined a plateau as less than 5% weight change over a 12-week period and all later 12-week periods. That was a research definition, not a rule for your care. It does not mean you should wait 12 weeks to ask for help.
Maintaining earlier progress is meaningful. Your clinician can review your trend, nutrition, activity, sleep, medicines and treatment goals before deciding whether anything should change.
A steady next step
- If weighing is appropriate for you, compare readings taken under similar conditions and look at the longer-term trend.
- Keep regular, balanced meals. Do not respond by severely restricting food or increasing medication yourself.
- Review sleep, daily movement, strength exercise and constipation with your care team.
- Use a follow-up visit to agree on realistic goals. Consistency supports health, but no plan guarantees continuous weight reduction.
Know when to get help
Contact your clinician promptly
- Repeated vomiting or diarrhea, trouble keeping fluids down, very little urine or ongoing dizziness.
- Symptoms that stop you from eating enough or do not improve.
- New vision changes, or repeated low-blood-sugar readings if you monitor glucose.
- Questions about your dose, a missed dose, pregnancy or any new medicine.
Seek urgent medical care
- Severe, persistent stomach pain, especially if it spreads to your back, with or without vomiting.
- Upper stomach pain with fever or yellow skin or eyes.
- Severe bloating with vomiting or inability to pass stool or gas.
- Fainting, severe confusion or signs of severe dehydration.
Call 911 for trouble breathing, swelling of the face or throat, a seizure or loss of consciousness.
If you have severe, persistent stomach pain that could be pancreatitis, stop the medicine and seek medical help right away.
This is not a complete list of risks. Review the information supplied with your medicine. Semaglutide and tirzepatide have important thyroid-tumor warnings and are not appropriate for everyone, including people with a personal or family history of medullary thyroid carcinoma or MEN2. Tell your clinician about pregnancy plans and all medicines. Tirzepatide can reduce the effectiveness of oral birth-control pills; ask about a non-oral method or added barrier protection for four weeks after starting and after each dose increase.
Sources & further reading
- NIDDK: prescription medicines for weight management
- Joint clinical advisory: nutrition during GLP-1 therapy
- Semaglutide: Wegovy prescribing information
- Tirzepatide: Zepbound prescribing information
- Tirzepatide trials: a study-specific plateau definition
- NIDDK: how calorie needs change as body weight changes
Educational information, not personal medical advice. Approved-brand labels are referenced for general education and do not establish an approved schedule for compounded products. Your clinician determines whether treatment is appropriate. All medical care is overseen by Elite Care Health.
